- •Table of Contents
- •Copyright
- •Contributors
- •How to Use this Study Guide
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •4: Outcomes Research
- •Questions
- •Answers
- •5: Core Principles of Perioperative Care
- •Questions
- •Answers
- •Questions
- •Answers
- •7: Principles of Urologic Endoscopy
- •Questions
- •Answers
- •8: Percutaneous Approaches to the Upper Urinary Tract Collecting System
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •12: Infections of the Urinary Tract
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •15: Sexually Transmitted Diseases
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •20: Principles of Tissue Engineering
- •Questions
- •Answers
- •Questions
- •Answers
- •22: Male Reproductive Physiology
- •Questions
- •Answers
- •Questions
- •Answers
- •24: Male Infertility
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •28: Priapism
- •Questions
- •Answers
- •Questions
- •Answers
- •30: Surgery for Erectile Dysfunction
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •34: Neoplasms of the Testis
- •Questions
- •Answers
- •35: Surgery of Testicular Tumors
- •Questions
- •Answers
- •36: Laparoscopic and Robotic-Assisted Retroperitoneal Lymphadenectomy for Testicular Tumors
- •Questions
- •Answers
- •37: Tumors of the Penis
- •Questions
- •Answers
- •38: Tumors of the Urethra
- •Questions
- •Answers
- •39: Inguinal Node Dissection
- •Questions
- •Answers
- •40: Surgery of the Penis and Urethra
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •47: Renal Transplantation
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •50: Upper Urinary Tract Trauma
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •53: Strategies for Nonmedical Management of Upper Urinary Tract Calculi
- •Questions
- •Answers
- •54: Surgical Management for Upper Urinary Tract Calculi
- •Questions
- •Answers
- •55: Lower Urinary Tract Calculi
- •Questions
- •Answers
- •56: Benign Renal Tumors
- •Questions
- •Answers
- •57: Malignant Renal Tumors
- •Questions
- •Answers
- •Questions
- •Answers
- •59: Retroperitoneal Tumors
- •Questions
- •Answers
- •60: Open Surgery of the Kidney
- •Questions
- •Answers
- •Questions
- •Answers
- •62: Nonsurgical Focal Therapy for Renal Tumors
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •66: Surgery of the Adrenal Glands
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •71: Evaluation and Management of Women with Urinary Incontinence and Pelvic Prolapse
- •Questions
- •Answers
- •72: Evaluation and Management of Men with Urinary Incontinence
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •76: Overactive Bladder
- •Questions
- •Answers
- •77: Underactive Detrusor
- •Questions
- •Answers
- •78: Nocturia
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •82: Retropubic Suspension Surgery for Incontinence in Women
- •Questions
- •Answers
- •83: Vaginal and Abdominal Reconstructive Surgery for Pelvic Organ Prolapse
- •Questions
- •Answers
- •Questions
- •Answers
- •85: Complications Related to the Use of Mesh and Their Repair
- •Questions
- •Answers
- •86: Injection Therapy for Urinary Incontinence
- •Questions
- •Answers
- •87: Additional Therapies for Storage and Emptying Failure
- •Questions
- •Answers
- •88: Aging and Geriatric Urology
- •Questions
- •Answers
- •89: Urinary Tract Fistulae
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •92: Tumors of the Bladder
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •95: Transurethral and Open Surgery for Bladder Cancer
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •99: Orthotopic Urinary Diversion
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Answers
- •Questions
- •Answers
- •108: Prostate Cancer Tumor Markers
- •Questions
- •Answers
- •Questions
- •110: Pathology of Prostatic Neoplasia
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •114: Open Radical Prostatectomy
- •Questions
- •Answers
- •Questions
- •Answers
- •116: Radiation Therapy for Prostate Cancer
- •Questions
- •Answers
- •117: Focal Therapy for Prostate Cancer
- •Questions
- •Answers
- •Questions
- •Answers
- •119: Management of Biomedical Recurrence Following Definitive Therapy for Prostate Cancer
- •Questions
- •Answers
- •120: Hormone Therapy for Prostate Cancer
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •124: Perinatal Urology
- •Questions
- •Answers
- •Questions
- •Answers
- •126: Pediatric Urogenital Imaging
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •133: Surgery of the Ureter in Children
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •137: Vesicoureteral Reflux
- •Questions
- •Answers
- •138: Bladder Anomalies in Children
- •Questions
- •Answers
- •139: Exstrophy-Epispadias Complex
- •Questions
- •Answers
- •140: Prune-Belly Syndrome
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •144: Management of Defecation Disorders
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •147: Hypospadias
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
- •152: Adolescent and Transitional Urology
- •Questions
- •Answers
- •Questions
- •Answers
- •154: Pediatric Genitourinary Trauma
- •Answers
- •Questions
- •Answers
- •Questions
- •Answers
2
Urinary Tract Imaging
Basic Principles of CT, MRI, and Plain Film
Jay T. Bishoff; Art R. Rastinehad
Questions
1.The measure of the potential adverse health effects of ionizing radiation in sieverts (Sv) is known as:
a.radiation exposure.
b.absorbed dose.
c.equivalent dose.
d.effective dose.
e.relative radiation levels.
2.The relative radiation level associated with abdominal computed tomography (CT) without and with contrast is:
a.none.
b.minimal, <0.1 mSv.
c.low, 0.1-1.0 mSv.
d.moderate, 1-10 mSv.
e.high, 10-100 mSv.
3.Bladder filling may precipitate autonomic dysreflexia in patients with a spinal cord injury above:
a.S2.
b.L4.
c.T10.
d.T12.
e.T6.
4.Radiation exposure diminishes as the square of the distance from the radiation
source. An exposure of 9 mSv at 1 foot from the source would be how much at 3 feet from the source?
a.0.09 mSv
b.1 mSv
c.3 mSv
d.9 mSv
e.27 mSv
5.Type 2 diabetics on oral metformin biguanide hyperglycemic therapy are at risk for biguanide lactic acidosis after exposure to intravascular radiological contrast media if they:
a.discontinue metformin 48 hours before the study.
b.have severe renal insufficiency and take metformin the day of the study.
c.are given a saline injection while taking metformin.
d.have normal kidney function and fail to stop metformin 48 hours before the study.
e.decrease metformin dose and increase other antihyperglycemic agents on the day of the study.
6.All of the following are true EXCEPT:
a.Patients with a history of asthma are at greater risk of having an adverse reaction to contrast media.
b.Severe allergic reactions are not dose dependent.
c.Hyperosmolar contrast media are more likely to cause contrast reactions than are iso-osmolar agents.
d.The mechanism of action associated with severe idiosyncratic anaphylactoid (IA) reactions is an immunoglobulin E (IgE) antibody reaction to the contrast media.
e.Severe cardiac disease is a risk factor for an adverse reaction to contrast media.
7.After rapidly assessing airway, breathing, and circulation, the medical treatment of choice for a severe, life-threatening adverse drug reaction following exposure to contrast media is:
a.subcutaneous injection of epinephrine 0.5 mg of 1 : 10,000 epinephrine.
b.intravenous injection of 100 mg of methylprednisone.
c.0.01 mg/kg of epinephrine (1 : 10,000 concentration), given intramuscularly in the lateral thigh.
d.intravenous diphenhydramine, 50 mg.
e.0.01 mg/kg of epinephrine (1 : 1000 concentration), given intramuscularly in the lateral thigh.
8.Which of the following is NOT a risk factor for developing contrast-induced nephropathy (CIN)?
a.Type 2 diabetes mellitus
b.Dehydration
c.Hypertension
d.Ventricular ejection fraction < 50%
e.Chronic kidney disease (glomerular filtration rate [GFR] <60 mL/min)
9.Nephrogenic systemic fibrosis (NSF) is:
a.a rare genetic condition exacerbated by the use of gadolinium-based contrast medium (GBCM).
b.immediately evident after exposure to gadolinium in 10% of exposed patients.
c.fibrosis of the skin, subcutaneous tissue, and skeletal muscle seen in patients with chronic hypertension exposed to gadolinium contrast medium.
d.not seen in patients with GFR > 60 mL/min/1.73 m2.
e.mainly seen in dialysis patients exposed to gadolinium contrast medium.
.During a diuretic renal scintigraphy:
a.the diuretic is administered approximately 2 minutes after peak activity is seen in the collecting system.
b.a T1/2 of greater than 14 minutes is consistent with obstruction.
c.99mTc-DMSA is the most sensitive for obstruction and determination of glomerular filtration rate.
d.intestinal or gallbladder activity should never be seen with 99mTcMAG3.
e.a T1/2 of less than 10 minutes is consistent with a nonobstructed system.
.Positron emission tomography (PET):
a.has a higher diagnostic accuracy than CT for seminoma and nonseminoma testis cancer following chemotherapy.
b.is sensitive and specific for detection of postchemotherapy teratoma.
c.Can be used with high positive predictive value within 2 weeks of completion of chemotherapy for bulky lymph adenopathy.
d.Has greater predictive value of primary disease in metastatic urothelial
carcinoma than magnetic resonance imaging (MRI).
e.Is able to detect local or systemic recurrence of prostate cancer in 74% of patients with prostate-specific antigen recurrence.
.What is the minimum estimated GFR for use of gadolinium-based contrast agents?
a.Less than 30 mL/min/1.73 m2
b.Greater than 50 mL/min/1.73 m2
c.Greater than 35 mL/min/1.73 m2
d.Greater than 30 mL/min/1.73 m2
e.There are no restrictions with patients with renal insufficiency.
.In magnetic resonance (MR) images using T2-weighted sequences, fluid appears as:
a.dark.
b.bright.
c.low signal.
d.signal void.
e.indeterminate.
.What lesions may have a high signal (bright) on T2-weighted MRI of the adrenal gland?
a.Pheochromocytoma
b.Metastasis
c.Adrenal cortical carcinoma (ACC)
d.None of the above
e.All of the above
.MR chemical shift imaging for adrenal adenoma takes advantage of which of the following phenomena to aid in the diagnosis?
a.Water and fat within the same voxels signals are canceled out in opposed-phase imaging.
b.Opposed-phase imaging will exhibit a high signal (bright).
c.Intracellular lipid content within an adenoma is low.
d.Intravenous contrast is required.
e.All of the above.
.Oncocytoma typically has been characterized by a central scar. Which other renal lesion may also exhibit a central scar on T2-weighted images?
a.Clear cell carcinoma
b.Angiomyolipoma
c.Chromophobe carcinoma